WHO Issues Warning Over Critical Lack of Obesity Medications

Under one in 10 people eligible to benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it releases its initial guidance on the medications.

With over a billion individuals worldwide currently obese, it is urging more widespread and fairer access to these injectable treatments.

According to estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.

"The latest guidance affirms that obesity is a chronic disease that can be addressed with thorough and continuous support," said the agency's head Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and supply-chain constraints are key barriers to widespread availability to the injections that can aid individuals in losing considerable weight, notes the organization.

Weight-Loss Drug Shortage

Even under the present best projected outlook, the supply of these medications would only suffice for approximately 100 million people – under 10% of eligible patients, per the WHO.

The recommendation encourages governments and firms to increase availability, via approaches including voluntary licensing.

A patent on a key compound – the primary ingredient of a leading brand – is scheduled to end in a number of countries in 2026.

How Obesity Drugs Operate

These medications replicate a biological compound to slow digestion, reduce hunger and boost satiety so individuals eat less.

Patients typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs.

Research suggests users may regain a significant portion after a year of discontinuing the treatment, because their usual food cravings resume.

Being above a healthy weight elevates your chance for experiencing diseases, like type 2 diabetes, heart disease, stroke, and specific cancers.

Obesity impacts individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, according to the health agency.